Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
Key facts
- Who runs it
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Where
- Burkina Faso, Gambia, Kenya, and Zambia4 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 192 people enrolled
- Started
- 28 Nov 2023
- Ended
- 29 Dec 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- M5717 60 mg
- Pyronaridine
- Atovaquone-Proguanil
- M5717 200 mg
- M5717 660mg
- Record updated
- 6 February 2026
Who can take part
- Age
- 12 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Participants with Asymptomatic Plasmodium falciparum Malaria with no Fever or other sign of Acute Uncomplicated Malaria and, with Microscopic confirmation using Giemsa-stained thick film, and a Parasitemia of >= 40 to <= 10,000 Asexual Parasites/Microliter (μL) of Blood
- Axillary Temperature < 37.0 degree Celcius (ºC) or oral/Tympanic/rectal Temperature< 37.5ºC; without history of fever during the previous 48 hours
- Have a body weight >= 45 kilogram (kg)
- Participants capable of giving Signed Informed consent which includes Compliance with the requirements and restriction listed in the Informed consent form
- Other Protocol defined Inclusion Criteria could apply
Who cannot take part
- Participants with any Preplanned surgery during the study
- Participants with any previous Treatment with pyronaridine as part of a combination therapy during the last 3 months
- Participants with any disease requiring Chronic Treatment
- Participants with any adequate Hematological, Hepatic, and renal function as defined in the Protocol
- Other protocol defined Exclusion Criteria could apply
Where is this trial?
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.
The 4 groups in the trial
- Cohort 1: M5717 (60 mg) + PyronaridineTreatment being tested
Participants received single oral dose of M5717 60 milligram (mg) plus pyronaridine tetraphosphate (pyronaridine) 720 mg (Participants \>= 65 kilogram \[kg\]) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
Treatment: M5717 60 mg and Pyronaridine
- Cohort 2: M5717 (200 mg) + PyronaridineTreatment being tested
Participants received single oral dose of M5717 200 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
Treatment: Pyronaridine and M5717 200 mg
- Cohort 3: M5717 (660 mg)+ PyronaridineTreatment being tested
Participants received single oral dose of M5717 660 mg plus pyronaridine 720 mg (Participants \>= 65 kg) or pyronaridine 540 mg (Participants \>= 45 to \< 65 kg) once daily in a single day treatment regimen.
Treatment: Pyronaridine and M5717 660mg
- Cohort 4: Atovaquone-proguanilTreatment being tested
Participants received orally 3 doses of Malarone (fixed-dose combination of atovaquone-proguanil) once daily in a 3-day treatment regimen.
Treatment: Atovaquone-Proguanil
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents With Plasmodium Falciparum Malaria Infection (CAPTURE-2)
- Record updated
- 6 February 2026